18:14 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

Abivax S.A. (Euronext:ABVX) said ABX464 improved mucosal healing rate (50% vs. 11%, p=0.03) and reduced partial (62% vs. 32%, p<0.02) and total Mayo Scores (53% vs. 37%, p<0.03) at eight weeks vs. placebo in 29...
18:46 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Abivax's ABX464 reduces HIV DNA in CD4+ T cells in Phase IIa

Abivax S.A. (Euronext:ABVX) reported top-line data from 9 HIV-infected patients in the first cohort of the open-label, Spanish Phase IIa ABX464-005 trial showed that once-daily 150 mg oral ABX464 for 28 days plus antiretroviral therapy...
16:54 , May 12, 2017 |  BioCentury  |  Product Development

Stepwise to a cure

Phase IIa data for ABX464 from Abivax S.A.S. are a step in the right direction toward a functional cure, but the company will need to show the therapy can achieve much greater reductions in HIV...
20:01 , May 5, 2017 |  BC Week In Review  |  Clinical News

ABX464 reduces HIV reservoirs in Ph IIa trial

Abivax S.A.S. (Euronext:ABVX) said ABX464 for 28 days reduced HIV reservoirs as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs) in the Phase IIa ABX464-004 trial to treat HIV infection. Specifically,...
22:36 , May 2, 2017 |  BC Extra  |  Clinical News

Abivax doubles on HIV reservoir readout

Abivax S.A.S. (Euronext:ABVX) rose €10.50 (114%) to €19.70 after it said results of a Phase IIa study showed ABX464 reduced HIV reservoirs in chronically infected HIV patients.The small molecule inhibits viral replication by preventing rev-mediated...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

ABX464: Phase IIa started

Abivax began the double-blind, placebo-controlled, European Phase IIa ABX464-004 trial to evaluate 50 mg oral ABX464 once daily for 28 days with Prezista darunavir plus ritonavir or with Prezista plus Tybost cobicistat in...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

ABX464: Additional Phase IIa data

Additional data from the double-blind, Mauritian and Thai Phase IIa ABX464-003 trial in treatment-naive patients with HIV infection showed that once-daily oral ABX464 led to a >=0.5 log reduction in viral load in 1 of...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

ABX464: Phase IIa data

Top-line data from the double-blind, placebo-controlled, dose-escalation, Mauritian Phase IIa ABX464-003 trial in about 80 treatment-naive patients with HIV infection showed that once-daily 150 mg oral ABX464 for up to 3 weeks led to a...
01:23 , Jun 26, 2015 |  BC Extra  |  Financial News

Abivax prices EUR $57.7M IPO

Abivax S.A.S. (Euronext:ABVX) raised EUR 57.7 million ($65.3 million) through the sale of 2.7 million shares at EUR 21.30 in an upsized IPO on Euronext Paris. Underwriters were RBC Capital Markets; Swiss Life Banque Privee;...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

ABX464: Phase IIa started

Abivax began a double-blind, placebo-controlled, Mauritian Phase IIa trial to evaluate 25, 50, 75, 100 and 150 mg oral ABX464 once daily or every 3 days for 2 weeks in about 80 treatment-naïve patients. Abivax...